Which has higher earnings & valuation, ABSI or PTCT?

PTC Therapeutics has higher revenue and earnings than Absci. PTC Therapeutics is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Absci $2.80M 540.57 -$115.18M -$0.80 N/A PTC Therapeutics $1.73B 3.34 $682.64M -$0.58 N/A

Is ABSI or PTCT more profitable?

PTC Therapeutics has a net margin of -3.80% compared to Absci's net margin of -7,756.38%. Absci's return on equity of -61.71% beat PTC Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Absci -7,756.38% -61.71% -54.52% PTC Therapeutics -3.80% -362.45% -1.32%

Does the media favor ABSI or PTCT?

In the previous week, PTC Therapeutics had 2 more articles in the media than Absci. MarketBeat recorded 7 mentions for PTC Therapeutics and 5 mentions for Absci. Absci's average media sentiment score of 1.18 beat PTC Therapeutics' score of 1.18 indicating that Absci is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Absci 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ABSI or XENE?

In the previous week, Xenon Pharmaceuticals had 10 more articles in the media than Absci. MarketBeat recorded 15 mentions for Xenon Pharmaceuticals and 5 mentions for Absci. Xenon Pharmaceuticals' average media sentiment score of 1.27 beat Absci's score of 1.18 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Absci 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xenon Pharmaceuticals 11 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, DNTH or ABSI?

Absci has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dianthus Therapeutics $1.90M 3,103.67 -$162.34M -$4.15 N/A Absci $2.80M 540.57 -$115.18M -$0.80 N/A

Does the media favor DNTH or ABSI?

In the previous week, Dianthus Therapeutics had 11 more articles in the media than Absci. MarketBeat recorded 16 mentions for Dianthus Therapeutics and 5 mentions for Absci. Absci's average media sentiment score of 1.18 beat Dianthus Therapeutics' score of 0.92 indicating that Absci is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Absci 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, LGND or ABSI?

Ligand Pharmaceuticals has higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ligand Pharmaceuticals $268.09M 21.24 $124.45M $9.35 30.55 Absci $2.80M 540.57 -$115.18M -$0.80 N/A

Does the media refer more to LGND or ABSI?

In the previous week, Absci had 2 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 5 mentions for Absci and 3 mentions for Ligand Pharmaceuticals. Absci's average media sentiment score of 1.18 beat Ligand Pharmaceuticals' score of 0.90 indicating that Absci is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Absci 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRSP or ABSI?

In the previous week, CRISPR Therapeutics had 5 more articles in the media than Absci. MarketBeat recorded 10 mentions for CRISPR Therapeutics and 5 mentions for Absci. Absci's average media sentiment score of 1.18 beat CRISPR Therapeutics' score of 0.36 indicating that Absci is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 0 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Absci 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Absci (ABSI) Competitors

$8.82 +0.02 (+0.23%)

As of 09/4/2026 04:00 PM Eastern

Compare

ABSI vs. PTCT, XENE, DNTH, LGND, and CRSP

Should you buy Absci stock or one of its competitors? Absci's main competitors and comparable companies include PTC Therapeutics (PTCT), Xenon Pharmaceuticals (XENE), Dianthus Therapeutics (DNTH), Ligand Pharmaceuticals (LGND), and CRISPR Therapeutics (CRSP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Absci compare to PTC Therapeutics?

Absci (NASDAQ:ABSI) and PTC Therapeutics (NASDAQ:PTCT) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

Absci presently has a consensus price target of $13.43, indicating a potential upside of 52.25%. PTC Therapeutics has a consensus price target of $98.55, indicating a potential upside of 42.20%. Given Absci's stronger consensus rating and higher possible upside, analysts clearly believe Absci is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Absci	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.64

52.1% of Absci shares are owned by institutional investors. 10.5% of Absci shares are owned by company insiders. Comparatively, 5.3% of PTC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, PTC Therapeutics had 2 more articles in the media than Absci. MarketBeat recorded 7 mentions for PTC Therapeutics and 5 mentions for Absci. Absci's average media sentiment score of 1.18 beat PTC Therapeutics' score of 1.18 indicating that Absci is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Absci	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PTC Therapeutics has a net margin of -3.80% compared to Absci's net margin of -7,756.38%. Absci's return on equity of -61.71% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Absci	-7,756.38%	-61.71%	-54.52%
PTC Therapeutics	-3.80%	-362.45%	-1.32%

PTC Therapeutics has higher revenue and earnings than Absci. PTC Therapeutics is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Absci	$2.80M	540.57	-$115.18M	-$0.80	N/A
PTC Therapeutics	$1.73B	3.34	$682.64M	-$0.58	N/A

Absci has a beta of 2.42, meaning that its share price is 142% more volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market.

Summary

Absci beats PTC Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Absci compare to Xenon Pharmaceuticals?

Absci (NASDAQ:ABSI) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

In the previous week, Xenon Pharmaceuticals had 10 more articles in the media than Absci. MarketBeat recorded 15 mentions for Xenon Pharmaceuticals and 5 mentions for Absci. Xenon Pharmaceuticals' average media sentiment score of 1.27 beat Absci's score of 1.18 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Absci	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	11 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

52.1% of Absci shares are held by institutional investors. Comparatively, 95.4% of Xenon Pharmaceuticals shares are held by institutional investors. 10.5% of Absci shares are held by company insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Absci has a beta of 2.42, suggesting that its share price is 142% more volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

Xenon Pharmaceuticals has a net margin of 0.00% compared to Absci's net margin of -7,756.38%. Xenon Pharmaceuticals' return on equity of -43.98% beat Absci's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Absci	-7,756.38%	-61.71%	-54.52%
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%

Absci has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Absci	$2.80M	540.57	-$115.18M	-$0.80	N/A
Xenon Pharmaceuticals	N/A	N/A	-$345.91M	-$4.74	N/A

Absci presently has a consensus target price of $13.43, suggesting a potential upside of 52.25%. Xenon Pharmaceuticals has a consensus target price of $77.13, suggesting a potential upside of 29.09%. Given Absci's higher possible upside, equities research analysts plainly believe Absci is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Absci	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Xenon Pharmaceuticals beats Absci on 9 of the 16 factors compared between the two stocks.

How does Absci compare to Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and Absci (NASDAQ:ABSI) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 52.1% of Absci shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 10.5% of Absci shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Absci has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$1.90M	3,103.67	-$162.34M	-$4.15	N/A
Absci	$2.80M	540.57	-$115.18M	-$0.80	N/A

In the previous week, Dianthus Therapeutics had 11 more articles in the media than Absci. MarketBeat recorded 16 mentions for Dianthus Therapeutics and 5 mentions for Absci. Absci's average media sentiment score of 1.18 beat Dianthus Therapeutics' score of 0.92 indicating that Absci is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Absci	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Absci has a net margin of -7,756.38% compared to Dianthus Therapeutics' net margin of -10,096.95%. Dianthus Therapeutics' return on equity of -22.53% beat Absci's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%
Absci	-7,756.38%	-61.71%	-54.52%

Dianthus Therapeutics presently has a consensus price target of $126.92, indicating a potential upside of 17.41%. Absci has a consensus price target of $13.43, indicating a potential upside of 52.25%. Given Absci's higher probable upside, analysts plainly believe Absci is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Absci	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Dianthus Therapeutics has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, Absci has a beta of 2.42, meaning that its share price is 142% more volatile than the broader market.

Summary

Absci beats Dianthus Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Absci compare to Ligand Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and Absci (NASDAQ:ABSI) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Ligand Pharmaceuticals has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market. Comparatively, Absci has a beta of 2.42, indicating that its stock price is 142% more volatile than the broader market.

Ligand Pharmaceuticals has higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	21.24	$124.45M	$9.35	30.55
Absci	$2.80M	540.57	-$115.18M	-$0.80	N/A

Ligand Pharmaceuticals presently has a consensus price target of $335.75, suggesting a potential upside of 17.56%. Absci has a consensus price target of $13.43, suggesting a potential upside of 52.25%. Given Absci's higher probable upside, analysts clearly believe Absci is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00
Absci	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, Absci had 2 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 5 mentions for Absci and 3 mentions for Ligand Pharmaceuticals. Absci's average media sentiment score of 1.18 beat Ligand Pharmaceuticals' score of 0.90 indicating that Absci is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Absci	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ligand Pharmaceuticals has a net margin of 67.88% compared to Absci's net margin of -7,756.38%. Ligand Pharmaceuticals' return on equity of 20.06% beat Absci's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	67.88%	20.06%	11.68%
Absci	-7,756.38%	-61.71%	-54.52%

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 52.1% of Absci shares are held by institutional investors. 5.6% of Ligand Pharmaceuticals shares are held by company insiders. Comparatively, 10.5% of Absci shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Ligand Pharmaceuticals beats Absci on 10 of the 16 factors compared between the two stocks.

How does Absci compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Absci (NASDAQ:ABSI) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

In the previous week, CRISPR Therapeutics had 5 more articles in the media than Absci. MarketBeat recorded 10 mentions for CRISPR Therapeutics and 5 mentions for Absci. Absci's average media sentiment score of 1.18 beat CRISPR Therapeutics' score of 0.36 indicating that Absci is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	0 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Absci	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CRISPR Therapeutics presently has a consensus target price of $68.06, indicating a potential upside of 21.99%. Absci has a consensus target price of $13.43, indicating a potential upside of 52.25%. Given Absci's stronger consensus rating and higher possible upside, analysts clearly believe Absci is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61
Absci	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

CRISPR Therapeutics has a net margin of -3,368.72% compared to Absci's net margin of -7,756.38%. CRISPR Therapeutics' return on equity of -24.39% beat Absci's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
Absci	-7,756.38%	-61.71%	-54.52%

CRISPR Therapeutics has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market. Comparatively, Absci has a beta of 2.42, indicating that its share price is 142% more volatile than the broader market.

Absci has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$11M	490.41	-$581.60M	-$4.76	N/A
Absci	$2.80M	540.57	-$115.18M	-$0.80	N/A

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 52.1% of Absci shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 10.5% of Absci shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Absci beats CRISPR Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Absci News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABSI vs. The Competition

Export

Metric	Absci	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.51B	$4.03B	$7.28B	$12.92B
Dividend Yield	N/A	3.60%	2.54%	8.90%
P/E Ratio	-11.03	12.65	272.43	25.42
Price / Sales	540.57	1,327.03	616.81	89.65
Price / Cash	N/A	107.40	77.39	52.28
Price / Book	6.17	16.15	12.85	6.17
Net Income	-$115.18M	-$22.76M	$3.47B	$349.50M
7 Day Performance	1.26%	0.30%	0.97%	-0.15%
1 Month Performance	5.00%	8.24%	5.46%	1.02%
1 Year Performance	258.54%	49.08%	24.28%	14.50%

Absci Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABSI Absci	2.8689 of 5 stars	$8.82 +0.2%	$13.43 +52.3%	+267.5%	$1.51B	$2.80M	N/A	210	Gap Down
PTCT PTC Therapeutics	3.75 of 5 stars	$69.54 -0.8%	$98.55 +41.7%	+19.5%	$5.85B	$1.01B	N/A	1,410	Positive News Analyst Upgrade
XENE Xenon Pharmaceuticals	2.5434 of 5 stars	$60.22 +0.4%	$77.13 +28.1%	+54.6%	$5.80B	$7.50M	N/A	210	Positive News Insider Trade
DNTH Dianthus Therapeutics	2.2896 of 5 stars	$105.61 -0.2%	$124.27 +17.7%	+338.4%	$5.79B	$2.04M	N/A	80	News Coverage Analyst Forecast Insider Trade
LGND Ligand Pharmaceuticals	3.8815 of 5 stars	$284.10 +1.3%	$335.75 +18.2%	+70.3%	$5.59B	$268.09M	30.39	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABSI) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Absci (ABSI) Competitors

ABSI vs. PTCT, XENE, DNTH, LGND, and CRSP

How does Absci compare to PTC Therapeutics?

Summary

How does Absci compare to Xenon Pharmaceuticals?

Summary

How does Absci compare to Dianthus Therapeutics?

Summary

How does Absci compare to Ligand Pharmaceuticals?

Summary

How does Absci compare to CRISPR Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABSI vs. The Competition

Absci Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Absci (ABSI) Competitors

ABSI vs. PTCT, XENE, DNTH, LGND, and CRSP

How does Absci compare to PTC Therapeutics?

Do analysts prefer ABSI or PTCT?

Do institutionals & insiders hold more shares of ABSI or PTCT?

Does the media favor ABSI or PTCT?

Is ABSI or PTCT more profitable?

Which has higher earnings & valuation, ABSI or PTCT?

Which has more volatility and risk, ABSI or PTCT?

Summary

How does Absci compare to Xenon Pharmaceuticals?

Does the media prefer ABSI or XENE?

Do insiders and institutionals believe in ABSI or XENE?

Which has more volatility and risk, ABSI or XENE?

Is ABSI or XENE more profitable?

Which has higher earnings and valuation, ABSI or XENE?

Do analysts recommend ABSI or XENE?

Summary

How does Absci compare to Dianthus Therapeutics?

Do institutionals & insiders have more ownership in DNTH or ABSI?

Which has preferable earnings & valuation, DNTH or ABSI?

Does the media favor DNTH or ABSI?

Is DNTH or ABSI more profitable?

Do analysts prefer DNTH or ABSI?

Which has more risk & volatility, DNTH or ABSI?

Summary

How does Absci compare to Ligand Pharmaceuticals?

Which has more risk & volatility, LGND or ABSI?

Which has preferable earnings and valuation, LGND or ABSI?

Do analysts rate LGND or ABSI?

Does the media refer more to LGND or ABSI?

Is LGND or ABSI more profitable?

Do insiders & institutionals hold more shares of LGND or ABSI?

Summary

How does Absci compare to CRISPR Therapeutics?

Does the media favor CRSP or ABSI?

Do analysts rate CRSP or ABSI?

Is CRSP or ABSI more profitable?

Which has more volatility and risk, CRSP or ABSI?

Which has better valuation & earnings, CRSP or ABSI?

Do institutionals & insiders believe in CRSP or ABSI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABSI vs. The Competition

Absci Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools